Systemic inflammation was highly prevalent in PreMiO patients with non-metastatic disease, as well as for those with metastatic disease; based on CRP measures for 56% of study patients, inflammation by cancer site ranged from 21% to 100% of M0 patients and 55% to 91% in M1 patients (Figure 6). Here, CRP is linked to cancer.